Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 4Small Cell Lung Carcinoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Pleural Effusion, Malignant 1Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Gastrointestinal Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

Bevacizumab 9Oxaliplatin 7Irinotecan 6Fluorouracil 6Nivolumab 5Leucovorin 5Cetuximab 5Capecitabine 5pembrolizumab 4Sunitinib 4IFL protocol 4Drug Therapy 4Cisplatin 4encorafenib 3Pemetrexed 3Gemcitabine 3Folfox protocol 35,10-methylenetetrahydrofolic acid 3trebananib 2trastuzumab deruxtecan 2amminedichloro(2-methylpyridine)platinum(II) 2Ocoxin 2N-(2-fluoro-4-((2-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)carbonylaminopyridin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide 2Levoleucovorin 2IDRX-42 2CGX1321 2130-nm albumin-bound paclitaxel 2zanidatamab 1ulixertinib 1tivozanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Gastrointestinal Neoplasms × rilotumumab × Clear all
NCT00788957 2024-08-07

Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC)

NantBioScience, Inc.

Phase 1/2 Completed
177 enrolled 31 charts
Gastrointestinal

Colonic Neoplasms, Gastrointestinal Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡